Overview

Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment

Status:
Unknown status
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the effects of Daratumumab with dexamethasone in subjects with relapsed or refractory multiple myeloma and renal impairment.
Phase:
Phase 2
Details
Lead Sponsor:
Hellenic Society of Hematology
Collaborator:
Janssen Pharmaceuticals
Treatments:
Antibodies, Monoclonal
BB 1101
Daratumumab
Dexamethasone
Dexamethasone acetate